The complement-targeted therapeutics market is expected to strengthen its roots in the global market at a strong CAGR of 22.9% between 2022 and 2032.
The global market holds a forecasted revenue of US$ 5.19 Bn in 2022 and is likely to cross US$ 33.20 Bn by the end of 2032.
The complement-targeted therapeutics market is anticipated to show promising growth prospects during the forecast period, expanding the complement-targeted therapeutics market share.
| Attributes | Details |
| CAGR (2022-2032) | 22.9% |
| Value (2022) | US$ 5.19 Billion |
| Value (2032) | US$ 33.20 Billion |
Demand for complement-targeted therapeutics is on the surge as they are widely used in patients that have a weaker complement cascade because of deficiency of some proteins or comparatively lower concentration.
Growing chronic diseases are pushing the sales of complement-targeted therapeutics as these diseases lower the proteins and weaken the complement cascade.
The complement cascade is a composition of 30 proteins that is a defence against infection and is encouraging many to opt for the same, thereby spiking the demand for complement-targeted therapeutics.
The complement-targeted therapeutics help in creating an immune response to foreign particles entered into the body for a patient that has a complement cascade is weaker, fuelling the demand for complement-targeted therapeutics.
Covid-19 has pushed the sales of complement-targeted therapeutics forward as the number of patients with chronic diseases has risen up as post-covid-19, fuelling the demand for complement-targeted therapeutics.
Demand for complement-targeted therapeutics is on the rise as complement-targeted therapeutics represent the vast potential for the mechanism by which the body responds to the infection.
The complement system eliminates particulate substances; furthermore, it also helps in modulating adaptive immune responses, thereby propelling the sales of complement-targeted therapeutics.
Complement-targeted therapeutics help in the normal mechanism of the immune system, fueling the sales of complement-targeted therapeutics.
There are a large number of clinical trials going on to evaluate the use of complement-targeted therapeutics in managing the body’s first response and normal immune system functioning.
With the increasing prevalence of immune system diseases and vast clinical research in complement-targeted therapeutics, it is expected to significantly fuel the demand for complement-targeted therapeutics.
The rising sales of complement-targeted therapeutics are also attributed to the growing prevalence of the geriatric population, whose body is comparatively more susceptible to infection due to a weak immune system.
The same is expected to drive the growth of complement-targeted therapeutics market share.
The increasing prevalence of chronic diseases is further expected to drive the demand for complement-targeted therapeutics.
However, a large proportion of the population living with complement deficiency goes undiagnosed, which may hamper the demand for complement-targeted therapeutics.
The global complement-targeted therapeutics market is expected to be dominated by North America due to higher product availability and is likely to witness a large number of sales of complement-targeted therapeutics.
Europe is expected to be the second most lucrative region and hold a considerable chunk of complement-targeted therapeutics market share owing to higher disease prevalence.
Latin America complement-targeted therapeutics market is expected to witness steady growth over the forecast period owing to increasing product availability in the region.
Asia-Pacific complement-targeted therapeutics market is expected to witness exponential growth over the forecast period owing to increasing product adoption for the treatment, fuelling the sales of complement-targeted therapeutics.
Middle East & Africa is expected to be the least lucrative region in the global complement-targeted therapeutics market due to least product adoption, expanding the complement-targeted therapeutics market share.
The key players in the complement-targeted therapeutics market are focusing on mergers and collaborations and the same is likely to fuel the sales of complement-targeted therapeutics.
Major players in the complement-targeted therapeutics market include Creative Biolabs, Complement UK, Novartis AG, Alexion Pharmaceuticals, PubMed Inc., Merck & Co., Inc., Pfizer Inc., Allergan plc, AbbVie.
Some of the recent developments in complement-targeted therapeutics market are as follows:
| Report Attribute | Details |
| Growth Rate | CAGR of 22.9% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2014 – 2020 |
| Forecast period | 2022 – 2032 |
| Quantitative units | Revenue in USD Billion, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Indication, Distribution Channel, Region |
| Regional scope | North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East and Africa |
| Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Creative Biolabs, Complement UK, Novartis AG, Alexion Pharmaceuticals, Inc. Merck & Co., Inc., Pfizer Inc., Allergan plc, AbbVie |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs |
North America holds the largest complement-targeted therapeutics market share owing to rapid growth of chronic diseases leading to a higher demand for complement-targeted therapeutics.
Key players holding substantial complement-targeted therapeutics market share include Creative Biolabs, Complement UK, Novartis AG, Alexion Pharmaceuticals, Inc. Merck & Co., Inc., Pfizer Inc., Allergan plc, and AbbVie.
Demand for complement-targeted therapeutics is likely to increase with their use in hospitals and healthcare units thereby thriving the sales of complement-targeted therapeutics in new markets.
Explore Similar Insights
Complement-targeted Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
